Skip to main content
MRNA
NASDAQ Life Sciences

Moderna Lifts FY Revenue Growth Outlook to 15%-25% After Q3 Beat

Tom Rudovsky · Reported by Seeking Alpha
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$265
Mkt Cap
$96.399B
52W Low
$22.28
52W High
$261
52W Position info
1089% above low
Off High info
at 52W high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

MRNA has more than doubled off its 52-week low of $22.28.

Summary

Moderna posted $162 million of Q3 net income, or $0.38 diluted EPS, on $1.3 billion of revenue, up 29% year over year, and raised its 2026 revenue growth outlook to 15%-25%, with the 2026 revenue forecast now at $2.236-$2.430 billion, above the $2.102 billion analyst estimate. It also now expects year-end cash of $8.1-$8.3 billion. The swing to profit is a sharp turn from the $782 million net loss reported in Q2, when the norovirus vaccine failed a Phase 3 interim look and a $950 million litigation settlement weighed on results. The raised outlook is the key new piece: management is now guiding to faster top-line growth than previously communicated, backed by the flu vaccine approval and COVID booster season. The stock is trading near its 52-week high, so the guidance raise extends a run that began with the August intismeran melanoma data.

Updated with a Benzinga report · What changed

Updates

  1. · Benzinga — Moderna raised its 2026 revenue forecast to $2.236-$2.430 billion, above the $2.102 billion analyst estimate, and now expects year-end cash of $8.1-$8.3 billion.

At the time of this announcement, MRNA was trading at $265.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $96.4B. The 52-week trading range was $22.28 to $261.00. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Seeking Alpha.


Price Chart

Share this article

Copied!

MRNA - Latest Insights

MRNA
Nov 06, 2026, 1:11 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $258.37
Real-time Price: $258.10 info
Change: -$0.275 (-0.11%) info
Market Cap: $103.041B info
MRNA
Nov 06, 2026, 6:47 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $252.01
Real-time Price: $258.07 info
Change: +$6.06 (+2%) info
Market Cap: $103.031B info
MRNA
Nov 06, 2026, 6:45 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $237.00
Real-time Price: $258.07 info
Change: +$21.07 (+9%) info
Market Cap: $103.031B info
MRNA
Nov 06, 2026, 6:45 AM EST
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $237.00
Real-time Price: $258.07 info
Change: +$21.07 (+9%) info
Market Cap: $103.031B info
MRNA
Nov 04, 2026, 11:43 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $247.22
Real-time Price: $258.07 info
Change: +$10.85 (+4%) info
Market Cap: $103.031B info